ABSTRACT

G-protein-coupled receptors (GPCR) belong to another important target class because they are involved in a variety of diseases such as asthma, AIDS, neurodegenerative and cardiovascular diseases [7]. However, technologies currently used have significant disadvantages as they typically involve the use of radioactively labeled ligands. This means exposure to hazardous radioactivity, limited shelf lifes of labeled components, and the production of radioactive waste on a large scale. Also, radioactive assays are still carried out in the standard 96-well format using volumes of 100-150 µl and are not easily amenable to miniaturization beyond the 384-well format (30-50 µl per well).